Cellular Intelligence is developing the first universal virtual cell-signaling model to understand and manipulate biological processes. This platform aims to shift biology from a deterministic state to one of designable outcomes. The company provides computational tools for advanced biological research and therapeutic development.
Funding
$10.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Current cell replacement therapies face challenges in efficiency, scalability, and robustness when producing diverse human cell types, particularly somite-derived cells essential for treating conditions like Duchenne muscular dystrophy and metabolic diseases. Traditional methods often lack the precision and speed required to optimize cell differentiation protocols effectively.
Solution
Somite.ai leverages a proprietary digital twin of the embryo and artificial intelligence to optimize protocols for generating somite-derived cells, including muscle, brown adipose, cartilage, bone, tendon, and dermis. By integrating data-rich sources like scRNA-Seq and gene expression databases, the digital twin simulates embryonic development, enabling rapid identification of novel protocols and regulators for cell differentiation. This AI-driven approach enhances the efficiency and scalability of cell replacement therapies, addressing the challenges of producing diverse human cell types with improved purity and yield. The company's technology facilitates the discovery of new signaling pathways and allows for rapid protocol optimization cycles, surpassing the limitations of established methods.
Target Audience
The primary target audience includes researchers and clinicians focused on cell replacement therapies for metabolic diseases, muscular dystrophies, joint and cartilage injuries, connective tissue syndromes, and severe burns.
Features
- Proprietary digital twin of the embryo constructed from scRNA-Seq, scATAC-seq, and gene expression databases
- AI-driven platform for identifying novel protocols for generating new cell types
- Computational analysis for discovering new regulators of cell differentiation
- Rapid protocol optimization cycles using machine learning
- Optimized protocols for generating muscle, brown adipose, cartilage, bone, tendon, and dermis cells
- Technology to increase purity of cell cultures without cell sorting procedures
- Exclusive license to founding patent from the French Association for Muscular Dystrophies (AFM) and INSERM